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OBJECTIVES: Congenital diseases such as haemophilia and
their treatment are inﬂuencing the every-day-life of patients and
their families and impact on their health-related quality of life
(HR-QoL). Haemophilia is a rare bleeding disorder in which
bleeding events can occur spontaneously or after minor traumas.
For the adequate assessment of HR-QoL validated instruments
are necessary. In the COCHE Study (Cost Of Care of Hemo-
philia) HR-QoL of adult haemophilia patients was assessed with
a newly developed disease-speciﬁc questionnaire, which was val-
idated in this study. METHODS: In the naturalistic, multicenter,
longitudinal COCHE Study 233 adult haemophilia patients
without inhibitors were enrolled from 23 Italian Haemophilia
Centers. HR-QoL was assessed together with information on
demographics, clinical and socio-economic outcomes. HR-QoL
was assessed with generic (SF-36, EQ-5D) and disease-speciﬁc
(Haem-A-QoL) instruments. Results will be presented concern-
ing HR-QoL assessed with Haem-A-QoL. RESULTS: Psycho-
metric characteristics of the pilot testing of Haem-A-QoL
questionnaire could be conﬁrmed in the COCHE Study. Patients
showed mainly impairments in the dimensions “sport”, “future”
and “physical health”. Most of them (75.6%) had to refrain
‘often’ or ‘always’ from sports like soccer, concerning their
“future” 48.5% thought ‘often’ or ‘always’ that their life plans
are inﬂuenced by their haemophilia. Pain in the joints was
reported ‘often’ or ‘always’ by 40.2%. Differences related to
socio-demographic data were found only for school level; people
with a low educational level showed signiﬁcantly more im-
pairments in their HR-QoL (“feeling”, “view”, treatment”,
“future”, “Total Score”) Signiﬁcant differences were shown as
well for clinical characteristics (severity, type of treatment, factor
concentrate, presence of infections, target joints); e.g. severely
affected patients showed higher impairments in their HR-QoL.
CONCLUSIONS: Haem-A-QoL is a short and well-accepted
questionnaire and shows quite satisfactory psychometric char-
acteristics (reliability, validity). Assessment of HR-QoL is impor-
tant to understand speciﬁc problems of haemophilic patients and
to improve their treatment.
PHM6
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN
ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO
PROPHYLACTIC REPLACEMENT TREATMENT
Ravera S1, Monzini M1, Gringeri A2, Mantovani LG1
1Center of Pharmacoeconomics, Milan, Italy; 2Haemophilia and
Thrombosis Centre, Milan, Italy
OBJECTIVES: Regular prophylactic replacement therapy has
been proved to provide a better quality of life in children with
haemophilia compared to those treated when bleeding occurs
(on-demand treatment). No data is available in adults. The aim
of this study is the evaluation and comparison of health-related
quality of life (HRQoL) in patients who switched from on-
demand therapy to prophylaxis. METHODS: A prospective,
open study design was chosen. Patients receiving on demand
treatment aged 18 years or more and affected by severe
haemophilia A were enrolled at two Italian haemophilia care
centres at the moment of their switching to prophylaxis therapy.
Information related to the on-demand treatment time period
(ODT), six months before enrolment, and to the prophylaxis
time period (PT), six months after enrolment, has been obtained
at baseline and at the end of the follow-up period. Two generic
HRQoL questionnaires, EuroQol (EQ-5D) and Short Form 36
(SF-36) have been used, higher score corresponding to better
quality of life. RESULTS: Ten patients returned HRQoL ques-
tionnaire: the median age was 31.9 years (ranging from 23 to 58
years). At the end of the follow-up period, SF-36 showed a sta-
tistically signiﬁcant improvement in patients quality of life in
some domains (“Physical Functioning” and “Bodily Pain”, p <
0.05) and in the Physical Component Summary (mean score after
ODT 43.9 vs. 48.3 after PT, p < 0.05). Results obtained with
EuroQol-5D were comparable to those showed by SF-36, with
signiﬁcantly different Visual Analogue Scale scores after ODT vs.
after PT (67.9 and 72.9 respectively, p < 0.05). CONCLUSIONS:
Prophylaxis therapy in adult patients with severe haemophilia
showed to provide a signiﬁcant improvement in HRQoL and it
should therefore be considered in a cost utility evaluation.
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OBJECTIVES: To review and evaluate available QOL instru-
ments in MDS, the QOL burden of MDS, disease characteristics
that inﬂuence QOL outcomes, and to provide recommendations
for future research. METHODS: A systematic literature review
was performed to identify QOL studies performed in MDS
patients and published in English from 1995 to 2005. RESULTS:
A total of 53 abstracts were located; 13 studies were selected for
review. The FACT-An, EORTC QLQ-C30, Quality of Life–E
(QOL-E), and SF-36 all demonstrated acceptable validity in
MDS patients. The FACT-An, QOL-E, and SF-36 had good inter-
nal consistency with Cronbach’s alpha coefﬁcients for subscales
ranging from 0.92 to 0.94, 0.72 to 0.88, and 0.75 to 0.94,
respectively. The FACT-An and EORTC QLQ-C30 showed
appropriate responsiveness to change in prospective randomized
trials. Two studies compared QOL among MDS patients with
the general population. Statistically signiﬁcantly (p < 0.05) worse
QOL was observed in the following domains: fatigue, physical
functioning, role physical, vitality, social functioning, emotional
functioning, and global health. Cognitive functioning was least
affected. No study stratiﬁed QOL differences by MDS disease
sub-group categories or International Prognostic Scoring System
(IPSS) risk scores. However, four studies established a link
between transfusion independence and better QOL. All studies
found QOL to be signiﬁcantly (p < 0.05) better in transfusion-
independent patients, even after controlling for haemoglobin
level. Six studies found improvements in clinical status were
associated with improved QOL. Changes in overall QOL were
mostly linked to improvements in the fatigue, dyspnea, physical,
and social functioning QOL sub-scales. CONCLUSIONS: MDS
leads to signiﬁcant QOL burden compared to similarly aged
adults in the general population. QOL is an important endpoint
in MDS research. Several validated instruments are available.
Evidence on the clear link between transfusion dependency and
impaired QOL suggests a potentially important role for new
treatments that achieve higher transfusion independence among
MDS patients.
